Navigation Links
Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa
Date:9/23/2013

Atlanta, September 23, 2013 A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting. The study confirmed a disease-specific-survival (DSS) rate of 95 percent when patients received fewer weeks of neoadjuvant (NEO) total androgen suppression (TAS).

The multi-institutional phase III trial, Radiation Therapy Oncology Group (RTOG) 9910, evaluated 1,490 intermediate-risk prostate cancer (PCa) patients from 152 institutions in the U.S. and Canada. Patients were accrued from 2000 to 2004 and followed for an average of 9 years, and the average age of the men was 71 at the time of accrual. The patients were stratified and randomized into two groups―Group 1 consisted of 752 patients who received eight weeks of NEO TAS, and Group 2 consisted of 738 patients who received 28 weeks of NEO TAS. Both groups then received eight weeks of external beam radiation therapy (RT) and concurrent TAS.

Cumulative incidence was used to estimate and test efficacy for DSS, prostate-specific antigen (PSA) failure, locoregional tumor progression and distant metastasis. Overall survival (OS) rates were estimated via the Kaplan-Meier method and efficacy tested with log rank. There were 30 PCa deaths in Group 1, for a 10-year DSS rate of 95 percent; and 24 PCa deaths in Group 2, for a 10-year DSS rate of 96 percent (no statistical difference). There were 200 additional deaths not attributable to PCa in Group 1 for a 10-year OS rate of 66 percent, and 196 such deaths in Group 2, for a 10-year OS rate of 67 percent. By 10 years, 27 percent of patients had a PSA failure (using the newer RTOG-ASTRO definition of nadir+2), 5 percent had PCa recurrence in the prostate (locoregional) and 6 percent had distant metastasis. Hot flashes and erectile dysfunction were more common in Group 2.

"Sometimes, preliminary research leads us to assume that more treatment is better, but this study serves as a strong cautionary note to put the promising treatment to the test," said Thomas Pisansky, MD, lead author of the study and professor of radiation oncology at the Mayo Clinic in Rochester, Minn. "Overall, both groups had very, very good outcomes, but patients assigned to Group 2 had more side effects from androgen suppression than Group 1, who received only eight weeks of NEO TAS. Now, investigators know the upper boundary of how much androgen suppression is needed in this group of patients. The results have substantial importance because they can alter the research strategy to one in which investigation can now concentrate on ways to simplify the treatment and further reduce side effects."


'/>"/>

Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. PeopleKeys Develops HR Filtering Tools in Response to Fewer Jobs, Increased Competition in Health Care
2. Twin Cities Home Sales Hit A Hot Summer Pace: 31.4 Percent Fewer Days
3. Longest and largest study of insulin pumps to treat type 1 diabetes in children shows they control blood sugar more effectively and with fewer complications than injections
4. Kwiksure Examines Why Drivers Have Fewer Accidents on Hong Kong Island than in the New Territories
5. Fewer states holding alcohol retailers responsible for harms from illegal service
6. Prostate cancers are fewer, smaller on walnut-enriched diet
7. Fewer Families Struggling to Pay Medical Bills: CDC
8. Healthy lifestyle choices mean fewer memory complaints, poll by UCLA and Gallup finds
9. Integrated stroke care system results in fewer deaths, discharges to long-term care facilities
10. Veterans Disability Appeals See Fewer Decisions in FY2012, Reports Allsup
11. Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate ... Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center ... been the gold standard for high-definition, in-ear earphones. This classic earphone has been ...
(Date:1/17/2017)... TX (PRWEB) , ... January 17, 2017 , ... Mirror ... have earned the highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice ... named part of this elite group of providers. , Produced by Zeltiq, CoolSculpting ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from ... primary eye care practitioners on the latest breakthroughs in the prevention, diagnosis and ... Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Neil H. Greco ... planning assistance to communities throughout the region, is launching a charity drive to raise ... is by far the deadliest killer in America, and is responsible for 1 in ...
(Date:1/17/2017)... ... ... Livionex, Inc., a Silicon Valley healthcare company focused on treating biofilms and ... gel that shows significant reduction in plaque levels and gum inflammation and bleeding when ... at the Beckman Laser Institute at UC Irvine and has been published in Dentistry, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017 North America Insulin ... new report, "North America Insulin Delivery Market Outlook to ... Insulin Delivery market. The report provides value, in millions ... (USD) within market segments - Insulin Pens, Insulin Pumps, ... report also provides company shares and distribution shares data ...
(Date:1/17/2017)... Jan. 17, 2017 The interventional radiology products ... 2021 from USD 6.35 billion in 2016, at a ... growth of this market are rising incidence of chronic ... invasive surgeries. The global interventional radiology products ... region. On the basis of type, the stents segment ...
(Date:1/17/2017)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... Phase 3 clinical trial comparing the efficacy and safety ... prevention of hepatic veno-occlusive disease (VOD) in adult and ... are at high risk or at very high risk ... conducted across approximately 100 medical centers in ...
Breaking Medicine Technology: